Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P46019
UPID:
KPB2_HUMAN
Alternative names:
-
Alternative UPACC:
P46019; A8K1T1; Q6LAJ5; Q7Z6W0; Q96CR3; Q9UDA1
Background:
Phosphorylase b kinase regulatory subunit alpha, liver isoform, encoded by the gene with accession number P46019, plays a crucial role in glycogen metabolism. It catalyzes the phosphorylation of serine in substrates such as troponin I and may interact with calmodulin. This protein's activity is essential for the proper functioning of liver and muscle tissues.
Therapeutic significance:
Glycogen storage disease 9A, a metabolic disorder characterized by mild liver glycogenosis and various clinical symptoms, is linked to mutations affecting this protein. Understanding the role of Phosphorylase b kinase regulatory subunit alpha could open doors to potential therapeutic strategies, offering hope for patients suffering from this condition.